127 related articles for article (PubMed ID: 8556394)
41. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
[TBL] [Abstract][Full Text] [Related]
42. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
Sherefa K; Sällberg M; Sönnerborg A
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
[TBL] [Abstract][Full Text] [Related]
43. Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D.
Pestano GA; Hosford KS; Spira AI; Riley J; Xie JM; Sewankambo N; Brown L; Ho DD; Boto WM
AIDS Res Hum Retroviruses; 1995 May; 11(5):589-96. PubMed ID: 7576915
[TBL] [Abstract][Full Text] [Related]
44. HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.
Becker Y
Virus Genes; 1994 Jul; 8(3):249-70. PubMed ID: 7975271
[TBL] [Abstract][Full Text] [Related]
45. Production of transmembrane and secreted forms of tumor necrosis factor (TNF)-alpha by HIV-1-specific CD4+ cytolytic T lymphocyte clones. Evidence for a TNF-alpha-independent cytolytic mechanism.
Liu AY; Miskovsky EP; Stanhope PE; Siliciano RF
J Immunol; 1992 Jun; 148(12):3789-98. PubMed ID: 1351088
[TBL] [Abstract][Full Text] [Related]
46. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
47. Correlation of maternal cytophilic human immunodeficiency virus (HIV)-1 V3 loop peptide-specific antibodies in infants with vertical HIV transmission.
Wang XP; Oyaizu N; Pahwa S
Pediatr Res; 1995 Sep; 38(3):384-9. PubMed ID: 7494664
[TBL] [Abstract][Full Text] [Related]
48. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.
Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
J Clin Invest; 1991 Sep; 88(3):876-84. PubMed ID: 1715888
[TBL] [Abstract][Full Text] [Related]
49. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
Stamatatos L; Lim M; Cheng-Mayer C
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
[TBL] [Abstract][Full Text] [Related]
50. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA
AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605
[TBL] [Abstract][Full Text] [Related]
51. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals.
Clerici M; Lucey DR; Zajac RA; Boswell RN; Gebel HM; Takahashi H; Berzofsky JA; Shearer GM
J Immunol; 1991 Apr; 146(7):2214-9. PubMed ID: 1826020
[TBL] [Abstract][Full Text] [Related]
52. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes.
Alexander-Miller MA; Parker KC; Tsukui T; Pendleton CD; Coligan JE; Berzofsky JA
Int Immunol; 1996 May; 8(5):641-9. PubMed ID: 8671651
[TBL] [Abstract][Full Text] [Related]
53. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
[TBL] [Abstract][Full Text] [Related]
54. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
55. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
56. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation.
Johnson RP; Trocha A; Buchanan TM; Walker BD
J Exp Med; 1992 Apr; 175(4):961-71. PubMed ID: 1372650
[TBL] [Abstract][Full Text] [Related]
57. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens.
Wilson SE; Habeshaw JA; Addawe MA; Hounsell EF; Oxford JS
AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1313-24. PubMed ID: 9339848
[TBL] [Abstract][Full Text] [Related]
58. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
Nehete PN; Vela EM; Hossain MM; Sarkar AK; Yahi N; Fantini J; Sastry KJ
Antiviral Res; 2002 Dec; 56(3):233-51. PubMed ID: 12406507
[TBL] [Abstract][Full Text] [Related]
59. Measurement of cerebrospinal fluid antibody to the HIV-1 principal neutralizing determinant (V3 loop).
Lucey DR; VanCott TC; Loomis LD; Bethke FR; Hendrix CW; Melcher GP; Redfield RR; Birx DL
J Acquir Immune Defic Syndr (1988); 1993 Sep; 6(9):994-1001. PubMed ID: 7688046
[TBL] [Abstract][Full Text] [Related]
60. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
